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Abstract
A bis-quinoline compound, (7-chloro-N-(4-(7-chloroquinolin-4-ylamino)butyl)quinolin-4-amine;
RE-660) was found to have C-C chemokine receptor type 1 (CCR1)-agonistic properties.RE-660
displayed strong adjuvantic activity in mice when co-administered with bovine α-lactalbumin used
as a model subunit protein antigen. RE-660 evoked a balanced Th1 (IgG2)/Th2 (IgG1) antibody
profile, and the quality of antibodies elicited by the bis-quinoline was found to be superior to that
evoked by glucopyranosyl lipid A by surface plasmon resonance experiments. No evidence of
proinflammatory activity was observed in human blood ex vivo models. In preliminary acute
toxicity studies, the compound was found to be of lower toxicity than chloroquine in mice, and
was non-mutagenic in an Ames screen.
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Since the discovery of adjuvanticity of aluminum salts by Glenny and coworkers,1
aluminum salt-based mineral salts (“alum”) have, until the recent introduction of
monophosphoryl lipid A (MPL),2 remained the only adjuvants currently approved by the
FDA. Aluminum salts are weak adjuvants, promoting Th2-skewed, rather than Th1-biased
humoral responses.3 They are ineffective at inducing cytotoxic T lymphocyte (CTL) or
mucosal IgA antibody responses, and exhibit the propensity of inducing IgE isotypes,3 the
basis of which is just beginning to be understood 4. The rapid convergence of innate
immunity,5 and the nascent field of TLRs (toll-like receptors),6 and other Pathogen-
Associated Molecular Pattern (PAMP)-recognizing elements7 are expected to contribute
significantly not only to the discovery and design of novel adjuvants, but also to their rapid
evaluation of potency and, importantly, safety.8
In an effort to aid the evaluation of both adjuvantic potency and proinflammatory activities
of relatively large focused libraries of compounds being generated by our synthetic
programs, we have adopted an approach that encompasses a detailed `immunoprofiling' of
representative members of known TLR agonists,9;10 as well as elucidating structure-activity
relationships of promising chemotypes.11–13 We report in this paper that simple,
synthetically facile, bis-quinoline compounds possess immunostimulatory and adjuvantic
properties without any apparent proinflammatory activity, and inducing robust, Th1-biased
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humoral responses in murine models. In contradistinction to our previous work on vaccine
adjuvants, this discovery was entirely accidental.
Our desire in evaluating TLR7/8 agonists as potential vaccine adjuvants11;12;14 had also
engendered an interest in TLR7/8 antagonists,15;16 because aside from its potential
therapeutic applications,17;18 we had hoped that we may glean from those molecules such
structural features as would be best avoided for purposes of designing and developing potent
adjuvants. We15 and others19 had observed that chloroquine selectively inhibits TLR7
signaling and, given that most TLRs signal via homo- or hetero-dimerization,20 we were
curious to examine dimeric 7-chloroquinolines, a chemotype that had previously been
evaluated for anti-malarial activity (Fig. 1).21
We found to our surprise that several bis-quinolines, but neither piperaquine nor
chloroquine, induced in apparently non-specific manner, NF-κB transactivation in virtually
all of our reporter cell lines (HEK-293 cells stably transfected with TLR2, TLR3, TLR4,
TLR5, TLR7, TLR8, TLR9, or Nod-1, and an NF-κB-secreted alkaline phosphatase [NF-
κB-SEAP] reporter gene; data not shown). Experiments with control (null) HEK-293 cells
stably transfected only with NF-κB-SEAP also yielded virtually identical results, with the
maximal response observed for RE-660 with a tetramethylene spacer bridging the quinoline
moieties (Fig. 2). The origin of the distinctly biphasic nature of NF-κB induction (Fig. 2) has
been observed for several immunostimulatory chemotypes11–13 is unclear, but was verified
not to be a consequence of cytotoxicity.
RE-660 showed no detectable proinflammatory (TNF-α, IL-1β, IL-6, IL-8, IL-12, IL-18) or
anti-inflamatory (IL-10) responses in whole human blood up to concentrations of 50 μM,
whereas LPS (TLR4 agonist),9 a dual TLR7/8 imidazoquinoline agonist that we had
characterized earlier,12 as well as CL-075 (TLR8 agonist),9 showed robust induction of all
of the above cytokines as previously described by us. Transcriptomal profiling in human
peripheral blood mononuclear cells also did not reveal any discernible signatures of
inflammation or immune activation (data not shown). A careful examination of the literature
indicated that certain bis-quinolines bind to zinc,22 and that such metal-bound ligands can
allosterically modulate chemokine receptor activity.23 RE-660, however, displayed no
propensity to interact with any of a wide range of metals as adjudged by absorption and
fluorescence spectroscopy, as well as by 1H NMR.
We elected to empirically screen for chemokine receptor agonistic activity, and we were
gratified to find that the compound was agonistic at CCR1 (C-C chemokine receptor type 1)
with an EC50 value of 2 μM (Fig. 3). No activity was detected with CCR2, CCR3, CXCR2,
or CXCR4 screens.
Mindful of recent observations that proinflammatory activity is not an absolute prerequisite
for adjuvantic properties,24 we decided to evaluate RE-660 in a murine model using bovine
α-lactalbumin as a test antigen despite the fact that the only tangible biomarker possibly
associated with any potential immunostimulatory activity was its CCR1-agonistic profile.
We deliberately chose to use outbred CF-1 mice that show neither the Th1 bias of C57/Bl6,
nor the Th2 bias observed in Balb/c mice.25 In a meta-analysis of 4 independent experiments
(5 animals per cohort, per experiment), RE-660 was found to have an adjuvantic activity
comparable to that of glucopyranosyl lipid A (GLA),26;27 a more potent analogue of
monophosphoryl lipid A (MPL), as evidenced by near-superimposable anti-α-lactalbumin
IgG titers (Fig. 4A), and better than that of PAM2CS, a prototype TLR2 agonist.13
Furthermore, we found in surface plasmon resonance experiments, that the quality of
antibodies elicited by RE-660 was superior to that of both GLA and PAM2CS, in terms of
sensorgram responses (avidity) and dissociation kinetics (off-rates) (Fig. 4B).
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Importantly, RE-660, like GLA, evoked a balanced Th1 (IgG2)/Th2 (IgG1) antibody profile,
whilst PAM2CS, as expected, showed a dominant Th2 response (Fig. 5). In our preliminary
evaluation of the safety of RE-660, no mutagenicity was detected in the standard Ames test.
In an acute lethality model, no mortality was observed up to doses of 100 mg/kg of RE-660.
In conclusion, a bis-quinoline compound, possessing CCR1-agonistic activity, and bereft of
any detectable proinflammatory-mediator inducing properties, was found to have potent
adjuvantic activity in a murine model of immunization with a small, soluble model subunit
protein antigen. However, we do not yet know if its adjuvantic property is causally related to
its CCR1-agonistic activity, and whether its adjuvantic activity would be preserved in non-
rodent species. We are excited, nonetheless, because the chemotype lends itself readily to
extensive structure-activity relationship analyses.
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Structures of the bis-quinoline compounds.
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NF-κB induction profiles by the bis-quinolines in a null-cell reporter gene assay (bottom).
Means and sd (quadruplicates) of a single representative experiment are shown.
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Dose-response profile of CCR1 agonism by RE-660 in CHO cells expressing hCCR1, and
measured by cellular dielectric spectroscopy with 10 nM human MIP-1α as positive control.
Means of duplicates of a representative experiment are shown.
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A. Geometric means and geometric standard deviations of anti-α-lactalbumin IgG (whole
molecule) of four independent experiments conducted a month apart. Outbred CF-1 mice
were used. Statistics are derived from 20 animals per cohort. B. Quality of antibody
determined by dissociation kinetics and sensorgram adsorption kinetics derived from
triplicate runs of surface-plasmon resonance experiments.
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Anti-α-lactalbumin IgG1 and IgG2a titers followingimmunization.Cohorts of 5 outbred
CF-1 mice per group wereimmunizedintramuscularlyon Day 0 with vehicle, 10μg/animal of
bovine α-lactalbumin alone,or 10 μg of α-lactalbumin mixed with 50 μg of either GLA,
PAM2CS, or RE-660 in a volume of 0.2 ml. Animals were boosted once on Day 14, and
bled on Day 21.
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